查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012642

人工智慧在糖尿病管理領域的市場：按設備類型、技術、組件、部署模式和最終用戶分類－2026-2032年全球市場預測

Artificial Intelligence in Diabetes Management Market by Device Type, Technology, Component, Deployment Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，糖尿病管理人工智慧 (AI) 市場價值將達到 13.1 億美元，到 2026 年將成長到 17.2 億美元，到 2032 年將達到 90.4 億美元，複合年成長率為 31.66%。

主要市場統計數據
基準年 2025 13.1億美元
預計年份：2026年 17.2億美元
預測年份 2032 90.4億美元
複合年成長率 (%) 31.66%

本文以引人入勝的方式介紹人工智慧，將其定位為重塑糖尿病照護服務管道、臨床實踐和病人參與的策略因素。

在人工智慧、數位健康整合和創新設備架構的驅動下，糖尿病管理的臨床和商業性格局正在經歷快速變化。本文闡述了人工智慧工具如何從實驗性試點階段走向主流臨床工作流程，並影響治療路徑、病人參與和系統級效能。此外，本文還建構了一個框架，闡述了技術成熟度、不斷變化的監管環境以及相關人員期望如何相互作用，共同塑造短期實施趨勢。

對人工智慧和互聯醫療驅動的系統性變革進行權威分析。這些變革正在重新定義糖尿病管理的臨床實踐模式、報銷機制和患者期望。

近年來，人工智慧與連網型設備的融合催生了新的護理標準，為糖尿病管理領域帶來了變革性的改變。臨床團隊正日益採用持續監測和演算法主導的胰島素給藥方式，以減少治療方案的變異性並實現個人化治療。同時，能夠整合生理和行為數據的軟體平台也使得更積極主動的預防性介入成為可能。這些變化反映了一個全新生態系統的興起：硬體進步、即時分析和雲端工作流程相互協作，從而能夠更深入地洞察血糖控制和風險趨勢。

對 2025 年實施的美國累積關稅如何重組整個糖尿病生態系統的供應鏈、籌資策略和產品開發重點進行嚴格檢驗。

美國於2025年開始實施的累積關稅政策，為糖尿病醫療設備和軟體的整個供應鏈帶來了獨特的壓力，也促使企業採取相應的策略應對措施。短期來看，關稅提高了進口零件和成品的成本，迫使製造商重新評估籌資策略，並盡可能加快供應鏈在地化進程。因此，企業開始仔細審查供應商關係和合約條款，採購團隊也開始專注於雙重採購、延長交貨週期以及提高前置作業時間彈性，以降低持續貿易政策波動的風險。

透過整合設備外形規格、技術堆疊、最終用戶畫像、部署模型、疾病亞型和組件優先級等詳細信息，可以深入了解細分市場，從而揭示可操作部署的關鍵因素。

要深入了解細分市場，需要細緻入微地理解設備外形規格、底層技術、使用者環境、部署模式、疾病類型和組件優先順序如何相互作用，從而影響部署和臨床效果。從設備角度來看，雖然血糖儀在自我監測和非侵入性應用情境中仍然重要，但更先進的連續血糖監測系統和胰島素輸注機制可支援封閉回路型自動化，從而減輕日常負擔。間歇掃描式血糖儀和即時連續血糖儀之間的差異，以及貼片式胰島素幫浦和管式胰島素幫浦之間的差異，導致了不同的使用者體驗和整合要求。另一方面，與混合配置相比，全封閉回路型系統需要更高的互通性和監管保障。

全面深入的區域洞察，詳細介紹美洲、歐洲、中東和非洲以及亞太地區的趨勢如何影響糖尿病解決方案的採用、監管參與和商業策略。

區域趨勢正從根本上影響糖尿病管理的整體情況，包括其應用路徑、報銷方式和供應鏈結構。在美洲，醫療保健系統對基於價值的模式和遠端監測功能表現出濃厚的興趣，這促使支付方更加關注以結果為導向的夥伴關係以及能夠體現患者層面可衡量改善的產品。北美醫療設備軟體相關法規的明確化正在推動整合醫療網路內的試點部署，而私人保險公司的發展趨勢則影響著解決方案的包裝和報銷方式。

企業級策略洞察，揭示競爭定位、夥伴關係模式、投資重點和能力，這些將決定人工智慧驅動的糖尿病護理領域的長期領導地位。

競爭格局由眾多參與者所構成，其中包括進軍軟體驅動型醫療領域的成熟醫療設備製造商、提供分析和平台服務的科技公司，以及專注於特定病患體驗和演算法創新的新興參與企業。市場領導者強調整合感測硬體、雲端分析和臨床決策支援等功能的整合產品組合，而中介軟體供應商則專注於連接不相容設備和電子健康記錄的互通性層。同時，以軟體為先導的公司透過複雜的演算法和使用者介面設計脫穎而出，旨在提升用戶參與度並簡化臨床醫生的工作流程。

產業領袖提出的實際建議，旨在加速推廣應用、建立信任並創建能夠推動可衡量的臨床結果的穩健經營模式。

產業領導者應推動一系列切實可行的舉措，將技術潛力轉化為可衡量的臨床和商業性成果。首先，應優先考慮互通性和開放標準，使設備和分析功能能夠整合到不同的臨床工作流程和電子健康記錄。這種方法將降低醫療服務提供者採用新技術的門檻，並促進多供應商生態系統的發展，從而擴大患者的選擇範圍。其次，應投資嚴格的臨床檢驗，將演算法輸出與臨床醫生的判斷和病患報告的結果相結合，以增強信心並為醫保報銷談判提供支援。此類證據對於將試點計畫轉化為標準化診療路徑至關重要。

我們採用高度透明的混合方法研究途徑，結合專家訪談、文獻整合和嚴格檢驗，產生了可操作和可複製的見解。

本分析的調查方法結合了定性和定量方法，以確保研究結果的穩健性、多方驗證性和可操作性。主要研究包括對臨床醫生、產品經理、採購負責人和監管專家進行深入訪談，並輔以專家圓桌會議，探討臨床應用和商業性路徑的障礙。次要研究則仔細審查了同儕審查文獻、監管指南、臨床試驗註冊資訊和企業資訊披露，以闡釋主要研究結果的背景，並識別主流技術趨勢和檢驗方法。

簡明結論強調，在臨床檢驗、互通性和商業設計方面的協作努力對於實現人工智慧驅動的糖尿病護理的益處至關重要。

總之，人工智慧與連網型設備創新技術的融合正在建立一種截然不同的糖尿病護理模式，該模式強調持續監測、個人化胰島素給藥和數據驅動的決策支援。積極主動地將產品設計、臨床檢驗和商業模式與不斷變化的監管環境和報銷趨勢相協調的相關人員將獲得先機。相反，如果機構將人工智慧僅視為一種功能而非護理路徑的組成部分，則可能面臨應用受限和影響分散的風險。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：糖尿病管理中的人工智慧市場：按設備類型分類

  • 血糖儀
    • 無創血糖儀
    • SMBG
  • 封閉回路型系統
    • 完全封閉回路型
    • 混合封閉回路型
  • 持續血糖監測
    • 間歇掃描式動態血糖監測
    • 即時動態血糖監測
  • 胰島素幫浦
    • 補片泵浦
    • 管式幫浦

第9章：糖尿病管理領域的人工智慧市場：按技術分類

  • 決策支援系統
    • 警報生成
    • 建議劑量
  • 機器學習
  • 行動應用
  • 預測分析
    • 預測血糖值的變化趨勢
    • 風險預測

第10章：糖尿病管理領域的人工智慧市場：按組件分類

  • 硬體
    • 泵浦
    • 感應器
    • 穿戴式裝置
  • 軟體
    • 演算法
    • 資料管理
    • 使用者介面

第11章：糖尿病管理中的人工智慧市場：依部署模式分類

  • 基於雲端的
    • 混合雲端
    • 公共雲端
  • 現場
    • 邊緣運算
    • 基於伺服器的

第12章：糖尿病管理中的人工智慧市場：按最終用戶分類

  • 診所
    • 糖尿病中心
    • 一般診所
  • 居家照護
    • 遠端監控
    • 自我管理
  • 醫院
    • 住院病人
    • 門診
  • 研究機構
    • 學術機構
    • 私人的

第13章：糖尿病管理領域的人工智慧市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：糖尿病管理領域的人工智慧市場：按群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：糖尿病管理領域的人工智慧市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國糖尿病管理領域的人工智慧市場

第17章：中國糖尿病管理領域的人工智慧市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Apple Inc.
  • Bigfoot Biomedical, Inc.
  • Dexcom, Inc.
  • Diabeloop SA
  • Eyenuk, Inc.
  • F. Hoffmann-La Roche Ltd
  • Glooko Inc.
  • Google LLC by Alphabet Inc.
  • Insulet Corporation
  • International Business Machines Corporation
  • Livongo Health, Inc.
  • Medtronic plc
  • Omada Health, Inc.
  • Tandem Diabetes Care, Inc.
  • Teladoc Health, Inc.
  • Tidepool Inc.
  • Virta Health Corp.
  • Wellthy Therapeutics Pvt. Ltd.
Product Code: MRR-4369010656EF

The Artificial Intelligence in Diabetes Management Market was valued at USD 1.31 billion in 2025 and is projected to grow to USD 1.72 billion in 2026, with a CAGR of 31.66%, reaching USD 9.04 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.31 billion
Estimated Year [2026] USD 1.72 billion
Forecast Year [2032] USD 9.04 billion
CAGR (%) 31.66%

A compelling introduction that contextualizes artificial intelligence as a strategic force reshaping diabetes care delivery pathways clinical practice and patient engagement

The clinical and commercial landscape for diabetes management is undergoing a rapid transformation driven by artificial intelligence, digital health integration, and novel device architectures. This introduction sets the stage for understanding how AI-enabled tools are moving from experimental pilots to mainstream clinical workflows, influencing care pathways, patient engagement, and system-level performance. It also frames the interplay between technology maturation, regulatory evolution, and shifting stakeholder expectations that together are shaping near-term adoption dynamics.

As stakeholders read on, they will find the report structured to highlight practical implications rather than purely theoretical advances. Clinicians and provider organizations must now evaluate how predictive analytics and decision support systems change point-of-care decision-making, while payers and administrators weigh the operational and financing implications of remote monitoring and closed loop solutions. Meanwhile, patients increasingly expect seamless, smartphone-driven experiences that reduce daily management burden and provide actionable insights. This introduction therefore positions AI not as a standalone innovation but as a force multiplier acting across devices, software, and care models, setting clear expectations for the subsequent sections that analyze transformative shifts, segmentation, regional dynamics, and actionable recommendations.

An authoritative analysis of the systemic shifts driven by AI and connected care that are redefining clinical practice models reimbursement design and patient expectations in diabetes management

The last few years have revealed transformative shifts in the diabetes management landscape as AI and connected devices converge to create new standards of care. Clinical teams are increasingly adopting continuous monitoring and algorithm-driven insulin delivery to reduce variability and personalize therapy; concomitantly, software platforms that aggregate physiological and behavioral data enable more proactive, preventive interventions. These shifts reflect an emergent ecosystem in which hardware advances, real-time analytics, and cloud-enabled workflows interact to produce higher-resolution insight into glycemic control and risk trajectories.

Moreover, regulatory frameworks and reimbursement policies are beginning to adapt to evidence of clinical benefit and operational value. As a result, vendor strategies have pivoted from selling standalone devices toward integrated solutions that combine sensors, algorithms, and care coordination services. Patient expectations are also evolving: convenience, interoperability with consumer devices, and transparent data-sharing modalities now influence product adoption. Collectively, these dynamics are accelerating the migration of diabetes management from episodic, clinic-centric care to continuous, data-driven modalities that emphasize prevention, personalization, and system-level efficiency.

A rigorous examination of how cumulative United States tariffs enacted in 2025 reshaped supply chains procurement strategies and product development priorities across the diabetes ecosystem

The imposition of cumulative United States tariffs in 2025 created a distinct set of stresses and strategic responses across the diabetes device and software supply chain. In the immediate term, tariffs increased input costs for imported components and finished devices, prompting manufacturers to re-evaluate sourcing strategies and to accelerate supply chain localization where feasible. The result has been a deliberate reassessment of supplier relationships and contractual terms, with procurement teams emphasizing dual sourcing, longer lead-time planning, and inventory resilience to mitigate exposure to ongoing trade policy volatility.

In parallel, product development and commercialization timelines experienced pressure as cost ceilings and margin expectations shifted. Some vendors absorbed incremental costs to preserve competitiveness, while others recalibrated pricing or deferred noncritical investments. For software-centric offerings, cloud hosting and cross-border data transfer arrangements required renewed legal and compliance scrutiny to ensure alignment with evolving trade and data policies. Over the medium term, tariffs acted as a catalyst for investment in domestic manufacturing capacity and for strategic partnerships that prioritize nearshoring, thereby strengthening regional supply networks and creating conditional opportunities for local suppliers and contract manufacturers to scale operations in response to demand.

Deep segmentation insights that integrate device form factors technology stacks end-user profiles deployment modalities disease subtypes and component priorities to reveal practical adoption levers

Segmentation insight requires a granular understanding of how device form factors, enabling technologies, user settings, deployment models, disease types, and component emphasis interact to influence adoption and clinical impact. From a device perspective, blood glucose meters remain relevant for self-monitoring and noninvasive use cases while more advanced continuous glucose monitoring systems and insulin delivery mechanisms support closed loop automation that reduces daily burden. Distinctions between intermittently scanned and real-time continuous monitors, and between patch and tubed pumps, drive different user experiences and integration requirements, while fully closed loop systems demand higher interoperability and regulatory assurance than hybrid configurations.

Technology choices matter because cloud computing options, decision support modules, machine learning approaches, mobile application platforms, and predictive analytics capabilities determine scalability and clinical utility. Public and private cloud architectures shape data governance and latency characteristics, while decision support functions range from alert generation to dosage recommendations. Machine learning implementations that use supervised, unsupervised, or reinforcement approaches will yield different validation needs and clinician acceptance pathways. End-user segmentation further clarifies where value accrues: clinics and diabetes centers prioritize workflow integration and specialist support, hospitals focus on inpatient and outpatient continuity, home care emphasizes remote and self-monitoring convenience, and research institutes demand flexible data access for hypothesis testing. Deployment modes-cloud-based versus on-premise-create trade-offs between scalability and control, with hybrid implementations increasingly common. Disease-type segmentation, including gestational care with trimester-specific needs, Type 1 adult and juvenile onset distinctions, and Type 2 insulin-dependent versus non-insulin-dependent cohorts, informs clinical protocols and device selection. Finally, the component-level split between hardware elements such as pumps and sensors and software capabilities like algorithms and user interfaces underscores where investment and regulatory oversight concentrate.

Comprehensive regional insights detailing how Americas Europe Middle East & Africa and Asia-Pacific dynamics influence adoption regulatory engagement and commercial strategy for diabetes solutions

Regional dynamics fundamentally shape adoption pathways, reimbursement approaches, and supply chain architecture across the diabetes management landscape. In the Americas, health systems demonstrate a strong appetite for value-based models and remote monitoring capabilities, driving payer interest in outcomes-oriented partnerships and in products that can demonstrate measurable patient-level improvements. North American regulatory clarity around medical device software has encouraged pilot deployments within integrated delivery networks, while commercial payer dynamics influence how solutions are packaged and reimbursed.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse care delivery contexts require adaptive market entry strategies that account for national reimbursement models, privacy standards, and infrastructure variability. Manufacturers seeking traction across this region must optimize for interoperability and localization, balancing centralized cloud architectures with on-premise or edge computing where bandwidth and data sovereignty concerns prevail. In the Asia-Pacific region, rapid technology adoption, high smartphone penetration, and increasing public investment in digital health create fertile ground for scalable AI-enabled solutions, yet market entrants must navigate varying clinical practice patterns, procurement rules, and localized expectations for affordability and after-sales support. Taken together, these regional nuances dictate differentiated commercial approaches, strategic partnerships, and regulatory engagement plans.

Strategic company-level insights that illuminate competitive positioning partnership models investment priorities and the capabilities that determine long-term leadership in AI-enabled diabetes care

The competitive landscape is defined by a mix of established medical device manufacturers expanding into software-enabled care, technology firms offering analytics and platform services, and nascent entrants focused on niche patient experiences or algorithmic innovation. Market leaders emphasize integrated portfolios that combine sensing hardware, cloud-based analytics, and clinician-facing decision support, while middleware providers concentrate on interoperability layers that connect disparate devices and electronic health records. Meanwhile, software-first companies differentiate through algorithmic sophistication and user interface design, targeting both consumer engagement and clinician workflow augmentation.

Investors and strategic partners are also influencing the trajectory of innovation by prioritizing companies that demonstrate robust clinical evidence, scalable deployment models, and clear pathways to reimbursement. Partnerships between device OEMs and cloud or analytics providers remain a dominant strategy to accelerate time-to-market and to broaden service offerings. For organizations assessing competitive positioning, attention should focus on product modularity, data governance practices, regulatory readiness, and the ability to demonstrate meaningful clinical outcomes in real-world settings.

Actionable recommendations for industry leaders to accelerate adoption build trust and create resilient commercial models that drive measurable clinical outcomes

Industry leaders should pursue a set of pragmatic actions to translate technological promise into measurable clinical and commercial outcomes. First, prioritize interoperability and open standards to ensure devices and analytics can integrate into diverse clinical workflows and electronic health records. This approach reduces friction for provider adoption and facilitates multi-vendor ecosystems that enhance patient choice. Second, invest in rigorous clinical validation that pairs algorithmic outputs with clinician adjudication and patient-reported outcomes to build trust and support reimbursement discussions. Such evidence is critical for transitioning pilots into standard care pathways.

Third, adopt supply chain resilience strategies that include dual sourcing, nearshoring where appropriate, and contractual flexibility to respond to trade-policy shifts. Fourth, design pricing and reimbursement models that align incentives across providers, payers, and patients, prioritizing value-based arrangements tied to demonstrable improvements in control and reduced acute events. Fifth, develop user-centered interfaces and mobile experiences that reduce cognitive load for patients and clinicians alike, ensuring adherence and sustained engagement. Finally, cultivate strategic partnerships across hardware, software, and clinical domains to accelerate innovation while mitigating execution risk.

A transparent mixed-methods research approach combining expert interviews literature synthesis and rigorous validation to produce actionable and reproducible insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to ensure robustness, triangulation, and practical relevance. Primary research consisted of in-depth interviews with clinicians, product leaders, procurement officers, and regulatory specialists, supplemented by expert roundtables that explored clinical adoption barriers and commercial pathways. Secondary research reviewed peer-reviewed literature, regulatory guidance, clinical trial registries, and company disclosures to contextualize primary findings and to identify prevailing technology trends and validation approaches.

Data synthesis employed thematic analysis for qualitative inputs and structured frameworks to assess technology readiness, interoperability, and business model viability. Where applicable, validation steps included cross-referencing interview insights with documented regulatory filings and publicly available clinical evidence. Ethical considerations were central to the methodology, with informed consent obtained from interview participants and careful anonymization applied where requested. The outcome is a research product that emphasizes reproducible reasoning, transparent assumptions, and evidence-based conclusions designed to inform strategic decisions without relying on undisclosed proprietary datasets.

A concise conclusion highlighting the imperative for coordinated action across clinical validation interoperability and commercial design to realize AI-driven diabetes care benefits

In conclusion, artificial intelligence and connected-device innovation are converging to create a fundamentally different model of diabetes care-one that emphasizes continuous monitoring, personalized insulin delivery, and data-driven decision support. Stakeholders who move proactively to align product design, clinical validation, and commercial models with evolving regulatory and reimbursement landscapes will capture early advantage. Conversely, organizations that treat AI as a feature rather than as an integral component of care pathways risk limited adoption and fragmented impact.

The path forward requires collaboration among device manufacturers, software vendors, clinicians, payers, and policy makers to ensure that technological advances translate into real-world clinical benefits. By leveraging interoperability, prioritizing robust evidence generation, and designing sustainable business models, the industry can accelerate the shift from reactive management to proactive, personalized diabetes care that improves outcomes and reduces system burden.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Diabetes Management Market, by Device Type

  • 8.1. Blood Glucose Meter
    • 8.1.1. Non Invasive Bg Meter
    • 8.1.2. Smbg
  • 8.2. Closed Loop System
    • 8.2.1. Fully Closed Loop
    • 8.2.2. Hybrid Closed Loop
  • 8.3. Continuous Glucose Monitor
    • 8.3.1. Intermittently Scanned Cgm
    • 8.3.2. Real Time Cgm
  • 8.4. Insulin Pump
    • 8.4.1. Patch Pump
    • 8.4.2. Tubed Pump

9. Artificial Intelligence in Diabetes Management Market, by Technology

  • 9.1. Decision Support Systems
    • 9.1.1. Alert Generation
    • 9.1.2. Dose Recommendation
  • 9.2. Machine Learning
  • 9.3. Mobile Applications
  • 9.4. Predictive Analytics
    • 9.4.1. Glucose Trend Prediction
    • 9.4.2. Risk Prediction

10. Artificial Intelligence in Diabetes Management Market, by Component

  • 10.1. Hardware
    • 10.1.1. Pumps
    • 10.1.2. Sensors
    • 10.1.3. Wearable Devices
  • 10.2. Software
    • 10.2.1. Algorithms
    • 10.2.2. Data Management
    • 10.2.3. User Interface

11. Artificial Intelligence in Diabetes Management Market, by Deployment Mode

  • 11.1. Cloud Based
    • 11.1.1. Hybrid Cloud
    • 11.1.2. Public Cloud
  • 11.2. On Premise
    • 11.2.1. Edge Computing
    • 11.2.2. Server Based

12. Artificial Intelligence in Diabetes Management Market, by End User

  • 12.1. Clinic
    • 12.1.1. Diabetes Center
    • 12.1.2. General Clinic
  • 12.2. Home Care
    • 12.2.1. Remote Monitoring
    • 12.2.2. Self Monitoring
  • 12.3. Hospital
    • 12.3.1. Inpatient
    • 12.3.2. Outpatient
  • 12.4. Research Institute
    • 12.4.1. Academic
    • 12.4.2. Private

13. Artificial Intelligence in Diabetes Management Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Intelligence in Diabetes Management Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Intelligence in Diabetes Management Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Intelligence in Diabetes Management Market

17. China Artificial Intelligence in Diabetes Management Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Apple Inc.
  • 18.7. Bigfoot Biomedical, Inc.
  • 18.8. Dexcom, Inc.
  • 18.9. Diabeloop SA
  • 18.10. Eyenuk, Inc.
  • 18.11. F. Hoffmann-La Roche Ltd
  • 18.12. Glooko Inc.
  • 18.13. Google LLC by Alphabet Inc.
  • 18.14. Insulet Corporation
  • 18.15. International Business Machines Corporation
  • 18.16. Livongo Health, Inc.
  • 18.17. Medtronic plc
  • 18.18. Omada Health, Inc.
  • 18.19. Tandem Diabetes Care, Inc.
  • 18.20. Teladoc Health, Inc.
  • 18.21. Tidepool Inc.
  • 18.22. Virta Health Corp.
  • 18.23. Wellthy Therapeutics Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY NON INVASIVE BG METER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY NON INVASIVE BG METER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY NON INVASIVE BG METER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SMBG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SMBG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SMBG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY FULLY CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY FULLY CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY FULLY CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INTERMITTENTLY SCANNED CGM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INTERMITTENTLY SCANNED CGM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INTERMITTENTLY SCANNED CGM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REAL TIME CGM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REAL TIME CGM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REAL TIME CGM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PATCH PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PATCH PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PATCH PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TUBED PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TUBED PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TUBED PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALERT GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALERT GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALERT GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DOSE RECOMMENDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DOSE RECOMMENDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DOSE RECOMMENDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GLUCOSE TREND PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GLUCOSE TREND PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GLUCOSE TREND PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RISK PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALGORITHMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALGORITHMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALGORITHMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY USER INTERFACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY USER INTERFACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY USER INTERFACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY EDGE COMPUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY EDGE COMPUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY EDGE COMPUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SERVER BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SERVER BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SERVER BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DIABETES CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DIABETES CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DIABETES CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GENERAL CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GENERAL CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GENERAL CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REMOTE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REMOTE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REMOTE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SELF MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SELF MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SELF MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ACADEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 255. EURO